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Skin Injury
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Human skin can defend itself against potentially invading microorganisms by production of antimicrobial
peptides (AMPs). The expression of AMPs in atopic dermatitis (AD) is still emerging. To gain more insight into
the role of AMPs in AD, we systematically analyzed the expression of ribonuclease 7 (RNase 7), psoriasin, and
human b-defensins (hBD)-2 and -3 in AD compared with psoriatic and healthy control skin as well as after
experimental barrier disruption. Immunostaining revealed enhanced expression of all AMPs in the lesional skin
of untreated AD and psoriasis when compared with non-lesional skin and controls. Accordingly, induced in vivo
secretion of RNase 7, psoriasin, and hBD-2 was detected using ELISA on lesional skin in AD and in even higher
concentrations in psoriasis. The secretion of AMPs did not correlate with severity of AD and Staphylococcus
aureus colonization. Skin barrier disruption caused enhanced immunoreactivity of hBD-2 and hBD-3 after
24 hours. Strong secretion of RNase 7 was already detected after 1 hour, whereas hBD-2 secretion was
significantly enhanced after 24 hours only under occlusion. Thus, a disturbed skin barrier may trigger AMP
induction in AD and psoriasis. The functional role of AMP in AD, especially with regard to the control of
S. aureus colonization, needs further analysis.
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INTRODUCTION
In addition to serving as a physical barrier, human skin
harbors a chemical defense system based on the production
of antimicrobial lipids and proteins. Antimicrobial peptides
(AMPs) and proteins represent a diverse group of small,
mainly cationic endogenous proteins that show antimicrobial
activity against bacteria, fungi, and viruses. Extensive
research during the past decade has shown that human skin
and other epithelial tissues as well as various leukocytes
are able to produce a wide variety of AMPs (Harder and
Schro¨der, 2005b).
There is increasing evidence that several AMPs have an
important role in cutaneous defense, in particular the human
b-defensins (hBD)-2 and hBD-3 (Harder et al., 1997, 2001;
Schro¨der and Harder, 1999; Pazgier et al., 2006), the S100
protein psoriasin (S100A7c) (Gla¨ser et al., 2005), the ribo-
nuclease 7 (RNase 7; Harder and Schro¨der, 2002), the cathe-
licidin LL-37 (Gudmundsson et al., 1996; Dorschner et al.,
2001; Nizet et al., 2001; Harder and Schro¨der, 2002), and the
sweat gland-derived dermcidin (Schittek et al., 2001). Many
of these AMPs are upregulated in keratinocytes upon contact
with microorganisms or microbial products (Harder and
Schro¨der, 2005a). This indicates that keratinocytes do not
merely function as a physical epidermal barrier, but rather
are active participants in innate defense by recognition of
microorganisms and subsequent initiation of innate immune
responses, such as the rapid induction of AMPs. AMPs are
also upregulated under inflammatory conditions and are
induced by inflammatory cytokines such as IL-1, IL-17, IL-22,
and tumor necrosis factor-a (Harder et al., 2007). Epidermal
differentiation and wound healing are other factors that
induce the expression of AMPs (Sorensen et al., 2003, 2006;
Harder et al., 2004). Various AMPs (e.g., hBD-2 and hBD-3
as well as LL-37) show immunomodulatory functions such
as recruitment and activation of antigen-presenting cells
(Oppenheim and Yang, 2005).
The role of AMPs in cutaneous biology may be reflected
by the increasing number of publications showing an asso-
ciation of AMPs with skin diseases. Several AMPs have been
isolated from psoriatic scales. Psoriatic skin is characterized
by a high expression of various AMPs that may be locally
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induced by microorganisms and endogenous proinflamma-
tory cytokines (Harder and Schro¨der, 2005b). The abundance
of AMPs in psoriatic skin offers an explanation as to why
patients with psoriasis suffer from fewer cutaneous bacterial
and viral infections than expected (Henseler and Christophers,
1995). In contrast to psoriasis, it has been reported that the
skin of patients suffering from atopic dermatitis (AD) is
characterized by an impaired induction of AMPs such as
hBD-2, hBD-3, LL-37, and dermcidin (Ong et al., 2002;
Nomura et al., 2003; de Jongh et al., 2005). Potential reasons
may include the lack of major AMP inducers in AD skin,
such as the cytokines IL-1, IL-17, and IL-22, as well as the
suppression of AMP induction by elevated levels of T-helper
2 cytokines, such as IL-4, IL-10, and IL-13. It has been
hypothesized that a reduced induction of AMPs in AD may
contribute to the increased susceptibility of AD skin to
Staphylococcus aureus infection (Boguniewicz and Leung,
2006). Most of the studies analyzing AMPs in AD, however,
compared AMP expression levels primarily with psoriatic but
not with healthy skin (Ong et al., 2002; de Jongh et al., 2005;
Guttman-Yassky et al., 2008). Recently, we observed that the
expression and secretion of psoriasin was strongly induced
in AD when compared with healthy skin, indicating that
the expression of AMPs is not generally impaired in AD
(Gla¨ser et al., 2009a).
To gain more insight into the role of AMPs in AD, we
systematically analyzed both the expression and the in vivo
secretion of two constitutively produced skin-derived
AMPs, RNase 7 and psoriasin, and of two inducible AMPs,
hBD-2 and hBD-3, in healthy, psoriatic, and chronic as
well as acute atopic skin. In this study, we show that all
four AMPs are induced in both non-lesional and lesional
skin of psoriatic and atopic patients when compared with
the skin of healthy individuals. As already reported for
psoriasin, superficial skin barrier disruption by tape stripping
in healthy skin also induced the expression of hBD-2, hBD-3,
and RNase 7, suggesting that the enhanced expression of
AMPs in psoriatic and AD skin may be driven by disrupted
epidermal barrier.
RESULTS
Enhanced AMP immunoreactivity in lesional and non-lesional
AD and psoriatic skin when compared with healthy controls
We used immunostaining to perform a comparative analysis
of the expression of RNase 7, psoriasin, hBD-2, and hBD-3 in
the same biopsies derived from normal as well as untreated
psoriatic and AD skin. Immunoreactivity of all analyzed
AMPs was increased in non-lesional AD (except hBD-2)
(Figure 1a) and psoriatic skin (Figure 1b) when compared
with skin derived from the same localizations of healthy
individuals. A further increment of immunoreactivity of all
AMPs was observed in the lesional skin of AD (Figure 1a)
and psoriasis (Figure 1b). Quantitative verification of AD
immunostainings by systematically scoring immunoreactivity
of all epidermal layers confirmed an upregulation of AMP
expression (Supplementary Table S1 online). These data
indicate that both AD and psoriasis are characterized by
an enhanced protein expression of the AMPs RNase 7,
psoriasin, hBD-2, and hBD-3, with the highest expression
levels in psoriasis.
Enhanced secretion of AMPs in lesional and non-lesional skin of
patients with AD and psoriasis when compared with healthy
controls
To analyze whether increased AMP expression, detected
using immunostaining, is associated with an enhanced
secretion of AMPs on the skin surface, we analyzed the
in vivo secretion levels of AMPs by determining the AMP
concentrations in skin-derived washing fluids. For this
purpose, washing fluids of standardized skin areas from
lesional and non-lesional skin of patients with untreated AD
(total n¼38; chronic AD n¼ 24 and acute AD n¼ 14) and
psoriasis vulgaris (n¼8) as well as matched controls (n¼34)
were analyzed for AMP levels using ELISA.
Significantly higher RNase 7 levels were detected in the
lesional skin of chronic and acute AD as well as psoriasis
patients when compared with non-lesional skin and healthy
controls (Figure 2a). There was no significant difference
when comparing the amounts of RNase 7 in non-lesional
skin of AD or psoriasis patients with healthy controls
(Figure 2a).
The psoriasin concentration of lesional and non-lesional
skin of chronic and acute AD patients was significantly
increased with respect to healthy controls (Figure 2b). These
data confirm our recent study (Gla¨ser et al., 2009a), but
include now a higher sample size and a characterization of
the respective bacterial load of the skin areas (see below). A
similar pattern was observed for psoriatic skin. The levels of
psoriasin were significantly increased in the non-lesional and
lesional psoriatic skin when compared with healthy controls
(Figure 2b).
The amounts of hBD-2 derived from the surface of
lesional skin of AD patients were significantly higher than
the amounts detected on the surface of healthy controls
(Figure 2c). The same pattern was observed in psoriasis
with much higher mean concentrations of secreted hBD-2.
No significance was found when comparing non-lesional
skin of AD patients and healthy controls, despite a clear
trend toward higher levels in non-lesional AD skin
(Figure 2c). Levels of hBD-2 were higher in lesional skin
of acute AD when compared with chronic AD. Lesional
skin of acute AD was characterized by significant higher
amounts of hBD-2 when compared with non-lesional skin
of acute AD and controls, a finding not observed for
chronic AD.
hBD-3 concentrations above the detection limit
(1.25 ngml–1) could only be detected in a couple of
lesional (total n¼6; chronic n¼ 1 and acute n¼5) and
non-lesional (total n¼ 3; chronic n¼ 2 and acute n¼ 1) AD
as well as lesional (n¼ 3) and non-lesional (n¼ 2) psoriasis
samples and were therefore not included in the statistical
analysis.
In general, the secreted amounts of AMPs in psoriasis were
higher than the levels detected in AD (Figure 2). The secreted
amounts of AMPs in AD were highest for psoriasin followed
by RNase 7 and hBD-2.
1356 Journal of Investigative Dermatology (2010), Volume 130
J Harder et al.
Antimicrobial Proteins in Atopic Dermatitis
RNase 7
Psoriasin
hBD-2
hBD-3
RNase 7
Psoriasin
hBD-2
hBD-3
PV LS PV NLS Control
AD LS AD NLS Control
Figure 1. Induction of antimicrobial peptide (AMP) expression in untreated atopic dermatitis and psoriasis skin samples. (a) Immunohistochemical analysis
of RNase 7, psoriasin, human b-defensin (hBD)-2, and hBD-3 of serial slides of the same skin biopsies derived from forearm lesional (AD LS) as well as
non-lesional skin from AD patients (AD NLS) and healthy controls. (b) Immunohistochemical analysis of RNase 7, psoriasin, hBD-2, and hBD-3 of serial slides
of the same skin biopsies derived from forearm lesional (PV LS) and non-lesional (PV NLS) skin from psoriasis vulgaris (PV) patients and healthy controls.
Samples from one representative person (AD¼ 4, PV¼4, controls¼8) are shown. Scale bar¼ 100mM.
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AMP secretion does not correlate with S. aureus colonization or
disease severity of AD
To analyze whether the expression of AMPs may correlate
with S. aureus colonization on the skin of AD patients, we
measured the colony-forming units (CFU) of S. aureus present
in skin washing fluids and performed correlation analyses
of skin-derived CFU with the according AMP levels.
First, we compared the CFU of S. aureus detected in
the skin washing fluids of AD patients with the severity of
AD symptoms measured by ‘‘SCORing of Atopic Dermatitis’’
(SCORAD). We found a statistically significant correlation
between S. aureus CFU and SCORAD (Figure 3a). In addition,
the S. aureus skin colonization rate was much higher in
patients with acute AD (93%) when compared with chronic
AD (46%). These results are consistent with published
findings (Guzik et al., 2005) and indicate the efficiency and
validity of our method. In contrast to the correlation bet-
ween severity of AD and S. aureus colonization, no signi-
ficant correlation was detected between the presence and
concentrations of AMPs (RNase 7, psoriasin, and hBD-2) on
AD skin and S. aureus CFU found on the identical skin
surface area (Figures 3b–d). In addition, there was no
correlation between AMP levels and coagulase-negative
Staphylococci, Micrococci, and Corynebacteria (data not
shown). Furthermore, no statistically significant correlation
between SCORAD and AMP secretion levels were detected
(Figures 3e–g).
Enhanced AMP immunoreactivity and secretion in normal skin
upon experimental barrier disruption
Both AD and psoriasis are characterized by a disturbed skin
barrier function. Recently, we have reported an increased
psoriasin expression upon superficial barrier disruption in AD
(Gla¨ser et al., 2009a). To elucidate whether superficial barrier
injury may also trigger the expression of RNase 7, hBD-2, and
hBD-3, we performed barrier disruption of healthy skin by
tape stripping until a transepidermal water loss of 40 gm–2
was reached. Immunohistochemistry of skin biopsies taken
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Figure 2. Enhanced secretion of antimicrobial peptides (AMPs) in non-lesional and lesional skin of chronic and acute atopic dermatitis (AD) and psoriasis
patients. The in vivo secretion levels of (a) RNase 7, (b) psoriasin, and (c) human b-defensin-2 (hBD-2) on chronic and acute AD as well as psoriasis skin
surface were analyzed by rinsing a defined skin area (0.55 cm2) followed by ELISA-based determination of AMP concentrations in the skin-derived washing
fluids. (c) Lesional skin (LS) and non-lesional skin (NLS) of untreated patients with chronic AD (n¼ 24, left panel), acute AD (n¼ 14, mean panel), and
psoriasis vulgaris (n¼8, right panel) were compared with matching normal controls. Bars indicate the mean concentration. Groups were compared using
the Wilcoxon signed-rank test. *Po0.05; **Po0.01; ***Po0.001.
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24 hours after tape stripping revealed an upregulation of
hBD-3 expression in the uppermost epidermal layers when
compared with untreated controls derived from correspond-
ing localizations (Figure 4a). RNase 7 immunoreactivity was
not induced by barrier disruption with and without occlusion,
whereas hBD-2 immunoreactivity was induced only under
occlusion after 24 hours (Figure 4a).
To analyze the influence of experimental barrier disrup-
tion on AMP secretion, we analyzed skin washing fluids at
different time points after tape stripping. The secretion of
RNase 7 increased significantly after 1 hour of barrier disrup-
tion independently of occlusion (Figure 4b). At 24 hours after
barrier disruption, RNase 7 expression was still enhanced but
the secretion levels differed only significantly from control
samples when occlusion was applied (Figure 4b). In contrast
to RNase 7, hBD-2 secretion was not induced after 1 hour
(Figure 4c). Only after 24 hours under occlusion a significant
induction of hBD-2 secretion was detected, confirming the
immunostaining experiments (Figure 4c). The secretion levels
of hBD-3 in all washing fluids were below the detection limit
of the ELISA (1.25 ngml–1).
DISCUSSION
Patients suffering from psoriasis have an unexpected low
incidence of cutaneous infection despite the presence of the
disrupted skin surface in psoriatic lesions (Henseler and
Christophers, 1995). This led to the idea that AMPs could
have an important role in the first-line defense of this disease.
Isolation of several AMPs from psoriatic lesional skin
supported a role of AMPs in protecting psoriatic skin from
infection (Harder et al., 2007). In line with this hypothesis,
our immunostaining experiments as well as the analysis of
AMP secretion on the skin surface revealed an enhanced
expression of psoriasin, RNase 7, hBD-2, and hBD-3 in
psoriatic skin.
In contrast to psoriasis, the role of AMPs in AD is still
emerging. The first studies reported a reduced expression of
AMPs in lesional skin of AD, leading to the logical and
straightforward hypothesis that an impaired expression and
induction of AMPs may contribute to the increased suscepti-
bility of atopic skin to infection, in particular with S. aureus
(Boguniewicz and Leung, 2006; Lin et al., 2007). However,
this issue seems to be more complex as in these studies the
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Figure 3. Antimicrobial peptide (AMP) secretion revealed no significant correlation with Staphylococcus aureus colonization or disease severity of atopic
dermatitis (AD). (a) Spearman’s rank correlation analysis of S. aureus colony-forming units (CFU) present in AD skin washing fluids (n¼38) with disease
severity of AD measured by ‘‘SCORing of Atopic Dermatitis’’ (SCORAD). (b–d) Spearman’s rank correlation analysis of S. aureus CFU present in AD skin
washing fluids (n¼ 38) with the concentration of (b) RNase 7, (c) psoriasin, and (d) human b-defensin-2 (hBD-2). (e–g) Spearman’s rank correlation analysis
of disease severity of AD measured by SCORAD with the concentrations of (e) RNase 7, (f) psoriasin, and (g) hBD-2.
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AMP expression was found reduced primarily in comparison
to lesional psoriatic skin (Ong et al., 2002; Nomura et al.,
2003; Howell et al., 2005; de Jongh et al., 2005; Guttman-
Yassky et al., 2008). Interestingly, Ong et al. (2002) detected
using immunohistochemistry higher hBD-2 staining in several
AD patients when compared with healthy controls, thus
providing first evidence of an increased expression of
antimicrobial peptides in AD skin. Therefore, we started to
systematically analyze and evaluate the role of several major
epidermal AMPs in a high number of chronic and acute AD
patients with respect to lesional and non-lesional skin,
disease severity, and bacterial burden, especially S. aureus.
A comparison with tissues samples and skin washing fluids
derived from healthy sex- and age-matched controls as well
as from patients with psoriasis vulgaris was performed. In
addition, we measured for the first time the in vivo AMP
protein secretion in correlation with SCORAD and S. aureus
colonization.
These analyses revealed an induction of all analyzed
AMPs in lesional AD skin compared with healthy controls.
The data indicate that the induction of AMPs is not generally
impaired in the skin of patients suffering from AD. However,
the absolute levels of AMP expression and secretion were
lower than levels detected in psoriasis, which is in agreement
with published results (Ong et al., 2002; Nomura et al., 2003;
de Jongh et al., 2005; Howell et al., 2005). Whether these
RNase 7
R
N
as
e 
7 
(ng
 m
l–1
)
hB
D
-2
 (n
g m
l–1
)
hBD-2
hBD-3
Untreated skin
25
20
15
10
5
0
0
1
2
3
4
5
6
Co 1 h 1 h+ 24 h+24 h Co 1 h 1 h+ 24 h+24 h
24 hours after skin
barrier disruption 24 hours under occlusion
Figure 4. Enhanced antimicrobial peptide (AMP) immunoreactivity and secretion in normal skin upon superficial barrier disruption. Superficial barrier
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quantitative differences may still explain the higher suscepti-
bility of AD skin with infections, especially by S. aureus, is
still emerging.
The lack of major AMP inducers in AD skin, such as IL-1,
IL-17, and IL-22, and suppression of AMP induction by
elevated levels of T-helper 2 cytokines, shown in vitro for
IL-4, IL-10, and IL-13, may explain the lower AMP levels in
AD when compared with psoriasis (Nomura et al., 2003;
Howell et al., 2005). Interestingly, our study revealed that in
patients with acute exacerbation of AD, secretion level of
RNase 7 and hBD-2 were higher when compared with
patients with chronic AD. In addition, hBD-3 was detect-
able in the lesional skin of six patients, five of whom were
characterized by acute exacerbation of AD. These in vivo
data indicate that elevated T-helper 2 cytokines, which have
been associated with acute AD, are not sufficient enough to
inhibit the induction of AMPs, such as RNase 7, hBD-2, and
hBD-3, in the acute AD lesion.
To gain further insight into the role of AMPs in regulating
S. aureus colonization in AD, we compared the secretion of
various AMPs with cutaneous colonization by S. aureus. First,
we verified a correlation of increased S. aureus colonization
with a higher SCORAD level (Guzik et al., 2005), confirming
the reliability of our method to analyze S. aureus in the skin
washing fluids. In contrast, we could not detect any
significant correlation between the secretion of AMPs (RNase
7, psoriasin, hBD-2, and hBD-3) and S. aureus colonization.
In addition, no significant correlation between AMP secretion
and SCORAD was detected. These data, together with the
observed upregulation of AMP in AD, support the hypothesis
that the increased susceptibility of AD skin to S. aureus
colonization and infection may not mainly be caused by
reduced amounts of AMP. However, we cannot exclude that
other AMPs not included in our study may have an important
role regarding S. aureus colonization in AD. It has been
shown, e.g., that the sweat-gland-derived AMP, dermcidin, is
deficient in the sweat of AD patients (Rieg et al., 2005).
Another explanation could be the expression of yet-unknown
factors inhibiting the antimicrobial activity of AMPs in AD
patients.
In accordance with our data, a recent publication by
Ballardini et al. (2009) reported enhanced expression of
LL-37 in lesional AD skin. Using quantitative PCR as well
as immunostaining they detected higher levels of LL-37 in
lesional skin than in non-lesional skin, but did not find any
correlation between LL-37 expression and severity of AD. In
addition, Gambichler et al. (2008) also reported messenger
RNA induction of AMPs in psoriasis and AD, although they
did not differentiate between epidermis and deeper compart-
ments of the skin and did not analyze AMP expression at the
protein level.
The enhanced expression of AMPs in AD skin may protect
the skin from colonization by different bacteria that are there-
fore not regularly found in AD. Psoriasin, e.g., as a potent
E. coli-cidal AMP may prevent cutaneous E. coli infections in
healthy as well as psoriatic and AD skin (Gla¨ser et al., 2005,
2009a; Harder and Schro¨der, 2005b). The in vivo relevance
of psoriasin for preventing colonization and infection with
E. coli has been shown by in vivo application of neutralizing
antibodies (Gla¨ser et al., 2005). The clinical observation that
E. coli does not represent a harmful germ in either psoriasis
or AD patients underlines this concept. Furthermore, the
induced expression of AMPs in AD skin may control a kind of
stable S. aureus colonization rate in these patients who rarely
develop severe deep tissue infections or sepsis despite the
disturbed skin barrier (Hanifin and Rogge, 1977). Accord-
ingly, a recent review of the literature revealed only a rare
number of cases of invasive S. aureus infections associated
with AD (Benenson et al., 2005).
Because AD is characterized by a chronically impaired
skin barrier function, we analyzed whether a disturbed
barrier influences the expression of AMPs. Recently, it was
shown that epidermal barrier disruption in mouse led to the
enhanced expression of the antimicrobial peptides mouse
b-defensin-3 and cathelin-related antimicrobial peptide
(Aberg et al., 2008). In our study we report for the first time
that a barrier disruption of healthy human skin leads to a
rapid secretion of RNase 7 already after 1 hour of superficial
skin injury by tape stripping. As RNase 7 shows a potent
broad spectrum of antimicrobial activity (Harder and
Schro¨der, 2002), the fast release of RNase 7 during cutaneous
injury may contribute to a rapid defense shield, protecting
superficially wounded skin from microbial colonization.
Interestingly, expression of hBD-2 was not induced by skin
barrier disruption alone, but only upon subsequent occlusion
for 24 hours. This may indicate that occlusion triggers the
expression of factors that selectively induce the expression of
hBD-2 but do not induce other AMPs, such as RNase 7 and
hBD-3. Prolonged occlusion of human skin may lead to
hyperhydration, which causes irritation, inflammation, and
cytokine induction (Warner et al., 2003). This sequence of
events is well known in occupational dermatology after
wearing occlusive gloves for several hours and this phenom-
enon may explain our observation of enhanced hBD-2
expression after occlusion.
Several metabolic events, e.g. increase in lipid synthesis,
are ameliorated by occlusion with an impermeable mem-
brane after skin barrier disruption (Grubauer et al., 1989).
However, occlusion also leads to irritation and induction of
cytokines (Wood et al., 1994). It has been shown that
induction of cytokines by skin barrier disruption in mouse
skin is only partially reduced by occlusion. Irritation is even
more pronounced after skin barrier disruption and occlusion
in human skin (Welzel et al., 1996). Therefore, the lacking
effect of occlusion on the reduction of RNase 7 and hBD-2
expression after skin barrier disruption does not mean that
skin barrier disruption is not the crucial factor. Nevertheless,
we cannot rule out that tissue damage itself, which also
releases cytokines, is an additional factor leading to increased
AMP synthesis.
Although we could not quantify hBD-3 secretion above
the detection limit of the ELISA in the skin washing fluids, the
immunostaining experiments revealed an upregulation of
hBD-3 after 24 hours of experimental barrier disruption. The
induction of hBD-3 after barrier disruption probably occurs
as a consequence of the induction of growth factors. Growth
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factors regulate hBD-3 expression (Sorensen et al., 2003) and
may be crucially involved in the repair of the superficial
wounds after skin barrier disruption without significant
inflammation. Expression of growth factors, however, seems
to be slightly reduced by occlusion after skin barrier
disruption (Liou et al., 1997). This may explain why hBD-3
expression is induced by skin barrier disruption alone but is
not further enhanced after occlusion. Recently, it has been
shown that sterile skin wounding induced by a scalpel led to
the enhanced expression of hBD-3 after 4 days, a process that
required the activation of the epidermal growth factor
receptor (Sorensen et al., 2006). Whether activation of the
epidermal growth factor receptor is also required for the
enhanced hBD-3 expression after superficial barrier disrup-
tion remains to be analyzed (Hirsch et al., 2009). In a very
recent paper it was shown that hBD-3 significantly promotes
wound closure in S. aureus-infected diabetic wounds
(Hirsch et al., 2009).
Recently, hBD-3 has been reported to serve as an
important AMP, participating in the antimicrobial activity of
normal human skin against S. aureus (Kisich et al., 2007). Our
immunostaining experiments clearly indicate that hBD-3 is
induced in non-lesional and lesional AD skin, denying a
general expression defect of hBD-3 in AD. However, in
the washing fluids hBD-3 was only hardly detectable in a
few samples. Even in the barrier disruption experiments,
no hBD-3 secretion above the detection limit of the ELISA
(1.25 ngml–1) could be observed, suggesting that the skin
secrets only low levels of hBD-3. However, given the strong
expression of hBD-3 in the immunostaining experiments, it is
also possible that hBD-3 is not efficiently elutable with
aqueous buffer solutions because the highly cationic hBD-3
may bind to negatively charged structures present in the
epidermis, which hampers an efficient release of hBD-3 into
the washing fluids.
In summary, the expression and secretion of the AMPs,
RNase 7, psoriasin, hBD-2, and hBD-3, is on one hand, as
reported previously, reduced in the skin of AD patients
when compared with psoriatic skin, and on the other,
clearly induced in comparison to healthy skin. In addition,
no correlation of AMP secretion and S. aureus colonization or
severity of AD was detected. Therefore, the frequent super-
infections of AD with S. aureus cannot be mainly explained
by a reduced expression of these AMPs. Consequently, the
functional role of AMPs in AD, especially with regard to the
control of S. aureus colonization, needs further investigation.
MATERIALS AND METHODS
Patients and controls
In total, 38 patients (0.5–72 years; 21 males and 17 females) affected
with atopic dermatitis, 8 patients with psoriasis vulgaris (5–64 years;
6 males and 2 females), and 34 healthy controls (0.7–65 years;
14 males and 20 females) were included in this study. All patients
had no specific treatment within the past 2 weeks. For immuno-
histochemical analysis each patient was assigned to a healthy
control matched in age, gender, and the site of skin biopsy. Severity
of symptoms was measured using SCORAD according to the
European Task Force (Kunz et al., 1997). The study was approved
by the University committee for ethical affairs, Kiel (AZ A 104/06), in
accordance with the guidelines of the Declaration of Helsinki
Principles. All participants included in this investigation provided
written informed consent.
Immunostaining
Punch biopsies were taken in local anesthesia from lesional and non-
lesional skin in AD patients (n¼ 4; forearm, trunk, and buttock),
psoriasis patients (n¼ 4; forearm, trunk, and thigh), and from
corresponding skin areas of sex- and age-matched healthy controls
(n¼ 8). Fixation of the tissue samples was performed in 4%
paraformaldehyde, and tissue sections (5mm) were deparaffinized
and rehydrated for the immunostaining experiments. The slides were
incubated for heat-induced antigen retrieval in 0.01M citrate buffer
(pH 6.0) at 90 1C for 80minutes. Subsequently, slides were blocked
with normal rabbit serum (1:75, Dako Cytomation, Glostrup,
Denmark) for 20minutes and immunohistochemical staining was
performed at room temperature using the antibodies and protocol as
previously described (Gla¨ser et al., 2009b). In addition, quantitative
scoring of AD immunostainings was performed (see Supplementary
Table S1 online).
Collection of skin-derived washing fluids
Washing fluids of standardized skin (0.55 cm2) areas from lesional
and non-lesional skin of patients with untreated AD (total n¼ 38;
chronic AD n¼ 24 and acute AD n¼ 14) and psoriasis vulgaris
(n¼ 8) as well as matched controls (n¼ 34) were analyzed for AMP
levels using ELISA. In detail, the active secretion of RNase 7,
psoriasin, hBD-2, and hBD-3 in patients as well as in controls was
analyzed by rinsing the skin with 900 ml of 10mM sodium phosphate
buffer pH 7.4 containing 150mM NaCl (skin rinsing buffer). Samples
were mixed with 100 ml skin rinsing buffer containing 10% (wv–1)
bovine serum albumin (Sigma, Deisenhofen, Germany) and super-
natants were stored after centrifugation of samples in aliquots at
80 1C until further processing.
ELISA
Protein levels of RNase 7, psoriasin, hBD-2, and hBD-3 in the skin
washing fluids were measured using ELISA as previously described
(Gla¨ser et al., 2009b). The detection limit for ELISA was 0.3 ngml–1
for psoriasin and RNase 7, respectively, 0.075 ngml–1 for hBD-2, and
1.25 ngml–1 for hBD-3.
Bacteriology
Skin washing fluids were used for analysis of bacterial colonization
shortly before storing at 80 1C. Serial dilutions of the washing fluids
were plated on blood agar plates (MHS plate, BioMe`rieux, Marcy
l’Etoile, France) as well as on selective agar plates for S. aureus (SAID
plate, BioMe`rieux). All plates were cultured at 37 1C for 24–48 hours.
Growing bacteria were differentiated into S. aureus, Staphylococcus
epidermidis, Micrococcus, and Corynebacteria by using Gram-stain
and testing coagulase and catalase activity (BioMe`rieux).
Experimental disruption of the skin barrier
Tape stripping (Tesa Pack original, ultra strong, Tesa Ag, Hamburg,
Germany) of a standardized area of the forearm skin was performed
in healthy volunteers (n¼ 8, 25–50 years, 6 females and 2 males)
until a transepidermal water loss of 40 gm–2 h–1 monitored by
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Tewameter TM210 (Courage and Khazaka, Cologne, Germany) was
reached. Both forearms were treated as described above. Occlusion
was performed after experimental skin barrier disruption on one arm
for up to 24 hours to achieve an artificial reconstitution of the
epidermal barrier (Harris et al., 1997). Large Finn Chambers on
Scanpor were used for effective occlusion (Epitest Oy, Tuusula,
Finnland). In vivo washing fluids (10mM sodium phosphate buffer
containing 150mM NaCl, pH 7.4) derived from the untreated
forearm and the pre-treated area were collected at different time
points and the amounts of RNase 7, hBD-2, and hBD-3 were
analyzed using ELISA as described above. In addition, punch
biopsies were taken from the forearms before (control) and 24 hours
after skin barrier disruption for immunohistological analysis of
RNase 7, hBD-2, and hBD-3 expression (n¼ 3).
Statistics
Calculations were performed using Wilcoxon’s signed-rank test and
Spearman’s rank correlation analysis.
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